Errol Gould

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 2

Top Topics

Alcohol Use Disorder

Systemic Lupus Erythematosus

Estrogen Receptor

Top Venues

Diabetes, metabolic syndrome and obesity : targets and therapy

International journal of obesity (2005)

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Dahlberg, Ellen T Chang, Sheila R Weiss, Pamela Dopart, Errol Gould, Mary E Ritchey
Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review. Diabetes, metabolic syndrome and obesity : targets and therapy 15 (2022)
Sean Wharton, Peter Yin, Melonie Burrows, Errol Gould, Jessica Blavignac, Rebecca A G Christensen, Elham Kamran, Fernando Camacho, Maxime Barakat
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International journal of obesity (2005) 45 (8) (2021)